Eccogene
Clinical trials sponsored by Eccogene, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo pill aims to supercharge weight loss in obesity Results expected Oct 2026 (estimated)
- Can a promising NAFLD drug safely mix with other medicines? a trial seeks answers Results expected Dec 2026 (estimated)
- Healthy volunteers needed to test new fatty liver drug with and without food Results expected Apr 2027 (estimated)
- New drug combo targets fatty liver in major trial Results expected Sep 2027 (estimated)
-
Can a promising NAFLD drug safely mix with other medicines? a trial seeks answers
Disease control Recruiting nowThis trial investigates whether ECC4703, a potential new treatment for non-alcoholic fatty liver disease (NAFLD), changes how the body processes two other drugs: sulfasalazine and pitavastatin. Healthy adults aged 18 to 65 will take these drugs alone and then with ECC4703 to meas…
Phase 1 • Sponsor: Eccogene • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo targets fatty liver in major trial
Disease control Recruiting nowThis study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…
Phase 2 • Sponsor: Eccogene • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Healthy volunteers needed to test new fatty liver drug with and without food
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called ECC4703, being developed for a serious fatty liver condition (MASH). Researchers want to see how taking the drug with or without food changes the amount that gets into the blood. 72 healthy adults will receive a single dose of the dr…
Phase 1 • Sponsor: Eccogene • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC